一线降压药物类别的综合比较有效性与安全性:一项系统性、多国、大规模分析
该研究采用新用户队列设计,基于6个行政索赔数据库和3个电子健康记录数据库,比较一线降压药物类别的有效性与安全性。
要点
- 噻嗪或噻嗪样利尿剂较血管紧张素转换酶抑制剂降低急性心肌梗死、心力衰竭住院和卒中风险。
- 非二氢吡啶类钙通道阻滞剂在有效性和安全性上显著劣于其他四类一线降压药。
- 多数一线降压药物类别之间在主要有效性结局上无显著差异,支持现行指南的等效性推荐。
核心结论
- 该框架支持一线降压单药治疗中药物类别间的等效性,与现行指南一致,但噻嗪或噻嗪样利尿剂优于血管紧张素转换酶抑制剂,非二氢吡啶类钙通道阻滞剂劣于其他四类。
主要发现
- 噻嗪或噻嗪样利尿剂较血管紧张素转换酶抑制剂降低急性心肌梗死风险(HR 0.84,95% CI 0.75-0.95)、心力衰竭住院风险(HR 0.83,95% CI 0.74-0.95)和卒中风险(HR 0.83,95% CI 0.74-0.95)。
- 噻嗪或噻嗪样利尿剂的安全性特征也优于血管紧张素转换酶抑制剂。
- 非二氢吡啶类钙通道阻滞剂显著劣于其他四类一线降压药物。
- 多数估计显示药物类别间无有效性差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uncertainty remains about the optimal monotherapy for hypertension, with current guidelines recommending any primary agent among the first-line drug classes thiazide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers, and non-dihydropyridine calcium channel blockers, in the absence of comorbid indications. Randomised trials have not further refined this choice. METHODS: We developed a comprehensive framework for real-world evidence that enables comparative effectiveness and safety evaluation across many drugs and outcomes from observational data encompassing millions of patients, while minimising inherent bias. Using this framework, we did a systematic, large-scale study under a new-user cohort design to estimate the relative risks of three primary (acute myocardial infarction, hospitalisation for heart failure, and stroke) and six secondary effectiveness and 46 safety outcomes comparing all first-line classes across a global network of six administrative claims and three electronic health record databases. The framework addressed residual confounding, publication bias, and p-hacking using large-scale propensity adjustment, a large set of control outcomes, and full disclosure of hypotheses tested. FINDINGS: Using 4·9 million patients, we generated 22 000 calibrated, propensity-score-adjusted hazard ratios (HRs) comparing all classes and outcomes across databases. Most estimates revealed no effectiveness differences between classes; however, thiazide or thiazide-like diuretics showed better primary effectiveness than angiotensin-converting enzyme inhibitors: acute myocardial infarction (HR 0·84, 95% CI 0·75-0·95), hospitalisation for heart failure (0·83, 0·74-0·95), and stroke (0·83, 0·74-0·95) risk while on initial treatment. Safety profiles also favoured thiazide or thiazide-like diuretics over angiotensin-converting enzyme inhibitors. The non-dihydropyridine calcium channel blockers were significantly inferior to the other four classes. INTERPRETATION: This comprehensive framework introduces a new way of doing observational health-care science at scale. The approach supports equivalence between drug classes for initiating monotherapy for hypertension-in keeping with current guidelines, with the exception of thiazide or thiazide-like diuretics superiority to angiotensin-converting enzyme inhibitors and the inferiority of non-dihydropyridine calcium channel blockers. FUNDING: US National Science Foundation, US National Institutes of Health, Janssen Research & Development, IQVIA, South Korean Ministry of Health & Welfare, Australian National Health and Medical Research Council.
引用
- Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019. PMID: 31668726. doi:10.1016/S0140-6736(19)32317-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。